A Phase 1 Pharmacokinetic And Pharmacodynamic Study Of PF-03446962 In Patients With Advanced Solid Tumors

Inclusion Criteria:

- Advanced measurable or non-measurable solid tumors

- Adequate bone marrow function

- Adequate liver function

- Adequate renal function

- Be able and willing to comply with the study scheduled visits, treatment plans,
laboratory tests and other procedures

Exclusion Criteria:

- Chemotherapy, radiotherapy, or any investigational cancer therapy within 4 weeks of
first dose of study medication

- Active bleeding disorder, including gastrointestinal bleeding, as evidenced by
hematemesis, hemoptysis or melena in the past 6 months

- Any of the following within the 12 months prior to starting study treatment:
myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
graft, congestive heart failure, cerebrovascular accident including transient
ischemic attack, or pulmonary embolus; or any other active thromboembolic event

- QTc prolongation defined as QTc >450 msec

- Patients with known brain metastasis

- Patients with peritoneal carcinosis at risk of bleeding

- Major surgical procedure within 4 weeks of treatment

- Pregnancy or breastfeeding